FATE THERAPEUTICS INC 8-K

What Happened

• Fate Therapeutics, Inc. (filed Form 8-K dated June 15, 2026) announced that its shareholders approved a third amendment and restatement of the company’s 2022 Stock Option and Incentive Plan (the "2022 A&R Plan"). The amendment increases the maximum number of shares available under the plan by 7,000,000 shares. The amended plan and related award agreement forms are filed as Exhibit 10.1 to the 8‑K. The filing is signed by CEO Bahram Valamehr, Ph.D., MBA.
• The filing also references Items 5.02 (departure/election of directors or certain officers) and 5.07 (submission of matters to a vote of security holders) as reported matters in the 8‑K.

Key Details

• Date of filing: June 15, 2026.
• Action approved: Third amendment and restatement of the 2022 Stock Option and Incentive Plan.
• Incremental shares added: 7,000,000 shares made available under the plan.
• Exhibit: Amended and restated plan and award agreement forms filed as Exhibit 10.1.

Why It Matters

• The amendment expands the pool of shares available for employee, director and consultant equity awards, enabling the company to grant additional stock options or other equity incentives for hiring, retention and compensation.
• If and when awards are granted and exercised, the change could increase the number of shares outstanding and dilute existing shareholders; investors should monitor future grant activity and the company’s total diluted share count.
• The filing is procedural (plan amendment and exhibit filing); there are no reported dollar amounts or immediate cash impacts disclosed in the 8‑K.